The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Udgivelsesdato: 2008-Nov
OriginalsprogEngelsk
TidsskriftEuropean Journal of Endocrinology
Vol/bind159
Udgave nummer5
Sider (fra-til)603-8
Antal sider5
ISSN0804-4643
DOI
StatusUdgivet - 1. nov. 2008

Fingeraftryk

Osteoprotegerin
Population
Libraries
Longitudinal Studies
Meta-Analysis
Prospective Studies

Citer dette

@article{ce678a90e14811dd9909000ea68e967b,
title = "The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review",
abstract = "OBJECTIVE: Osteoprotegerin (OPG) strongly inhibits bone resorption and may also serve as a vascular calcification inhibitor. However, recent studies have indicated that high plasma OPG is a strong predictor of cardiovascular disease (CVD) and mortality. To evaluate this capability, the data concerning OPG as a CVD predictor was gathered through a systematic literature review. DESIGN AND METHODS: Studies investigating OPG as a predictor of CVD or mortality were extracted from Medline and the Cochrane Library, retrieving 187 articles. Non-relevant articles were excluded, resulting in a total of 45 articles. After thorough evaluation of the abstracts, only eight prospective studies containing a follow-up period with a clinical emphasis on CVD were eligible for the literature review. RESULTS: All studies except one confirmed that OPG measurement adds important prognostic information to the existing markers of CVD and mortality in high-risk populations. Hazard ratios emphasized the significant correlation between plasma OPG concentration and mortality. Due to methodological problems (e.g., population investigated, measurement principle, and statistics performed), meta-analysis could not be performed. As only one study was conducted in a healthy cohort, the results cannot per se be extrapolated to the general population. CONCLUSION: The combined results support plasma OPG as an independent predictor of CVD and mortality in high-risk populations. However, more longitudinal studies in general cohorts are needed before the use of plasma OPG can be evaluated in this regard.",
keywords = "Cardiovascular Diseases, Humans, Osteoprotegerin, Predictive Value of Tests, Risk Factors",
author = "Mads Nybo and Rasmussen, {Lars M}",
year = "2008",
month = "11",
day = "1",
doi = "10.1530/EJE-08-0554",
language = "English",
volume = "159",
pages = "603--8",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "5",

}

The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. / Nybo, Mads; Rasmussen, Lars M.

I: European Journal of Endocrinology, Bind 159, Nr. 5, 01.11.2008, s. 603-8.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review

AU - Nybo, Mads

AU - Rasmussen, Lars M

PY - 2008/11/1

Y1 - 2008/11/1

N2 - OBJECTIVE: Osteoprotegerin (OPG) strongly inhibits bone resorption and may also serve as a vascular calcification inhibitor. However, recent studies have indicated that high plasma OPG is a strong predictor of cardiovascular disease (CVD) and mortality. To evaluate this capability, the data concerning OPG as a CVD predictor was gathered through a systematic literature review. DESIGN AND METHODS: Studies investigating OPG as a predictor of CVD or mortality were extracted from Medline and the Cochrane Library, retrieving 187 articles. Non-relevant articles were excluded, resulting in a total of 45 articles. After thorough evaluation of the abstracts, only eight prospective studies containing a follow-up period with a clinical emphasis on CVD were eligible for the literature review. RESULTS: All studies except one confirmed that OPG measurement adds important prognostic information to the existing markers of CVD and mortality in high-risk populations. Hazard ratios emphasized the significant correlation between plasma OPG concentration and mortality. Due to methodological problems (e.g., population investigated, measurement principle, and statistics performed), meta-analysis could not be performed. As only one study was conducted in a healthy cohort, the results cannot per se be extrapolated to the general population. CONCLUSION: The combined results support plasma OPG as an independent predictor of CVD and mortality in high-risk populations. However, more longitudinal studies in general cohorts are needed before the use of plasma OPG can be evaluated in this regard.

AB - OBJECTIVE: Osteoprotegerin (OPG) strongly inhibits bone resorption and may also serve as a vascular calcification inhibitor. However, recent studies have indicated that high plasma OPG is a strong predictor of cardiovascular disease (CVD) and mortality. To evaluate this capability, the data concerning OPG as a CVD predictor was gathered through a systematic literature review. DESIGN AND METHODS: Studies investigating OPG as a predictor of CVD or mortality were extracted from Medline and the Cochrane Library, retrieving 187 articles. Non-relevant articles were excluded, resulting in a total of 45 articles. After thorough evaluation of the abstracts, only eight prospective studies containing a follow-up period with a clinical emphasis on CVD were eligible for the literature review. RESULTS: All studies except one confirmed that OPG measurement adds important prognostic information to the existing markers of CVD and mortality in high-risk populations. Hazard ratios emphasized the significant correlation between plasma OPG concentration and mortality. Due to methodological problems (e.g., population investigated, measurement principle, and statistics performed), meta-analysis could not be performed. As only one study was conducted in a healthy cohort, the results cannot per se be extrapolated to the general population. CONCLUSION: The combined results support plasma OPG as an independent predictor of CVD and mortality in high-risk populations. However, more longitudinal studies in general cohorts are needed before the use of plasma OPG can be evaluated in this regard.

KW - Cardiovascular Diseases

KW - Humans

KW - Osteoprotegerin

KW - Predictive Value of Tests

KW - Risk Factors

U2 - 10.1530/EJE-08-0554

DO - 10.1530/EJE-08-0554

M3 - Journal article

C2 - 18697793

VL - 159

SP - 603

EP - 608

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 5

ER -